Eli Lilly and Company

ProQR Announces Year End 2023 Operating and Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Trident, Eli Lilly, Exercise, ProQR, Patient, IP, Therapy, Lilly, RNA editing, Cholestasis, Rett syndrome, Research, Cardiovascular disease, Partnership, Pseudouridine, NTCP, RNA, Functional, Uridine, MECP2, Oligonucleotide, ACTB, LPL, Annual report, Conference, Patent, Biomarker, Mouse, RSRT, Eli Lilly and Company, Liver, ANGPTL3

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2023, and provided a business update.
  • At December 31, 2023, ProQR held cash and cash equivalents of €118.9 million, compared to €94.8 million at December 31, 2022.
  • The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
  • For further financial information for the period ended December 31, 2023, please refer to our 2023 Annual Report on Form 20-F and our Statutory Annual Report which will be available on our website, www.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
Tuesday, March 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Health, Human Resources, Clinical Trials, Pharmaceutical, Biotechnology, Polyp (medicine), Organization, University, Internal medicine, Growth, UCSF, Immunotherapy, CFO, Critical Care Medicine (journal), Business, Inflammation, Patient, Roche, TSLP, Acquisition, Bryant University, MD, Senior, MBA, Biology, Asthma, Therapy, Ithaca College, National Jewish Health, Sinusitis, Eli Lilly and Company, Genzyme, Ironwood Pharmaceuticals, Babson College, Management

Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing verekitug (UPB-101) for respiratory disorders, today announced strategic leadership changes including the appointment of Rand Sutherland, MD, as Chief Executive Officer.
  • “I am thrilled to join Upstream Bio as CEO.
  • By evolving and building our leadership team with these additions, we are further positioning Upstream Bio to become a leader in the immunotherapy landscape.
  • I am pleased to welcome Rand, Mike and Lisa to the Upstream Bio team.”
    Dr. Sutherland joins Upstream Bio with more than 25 years of business and clinical experience, having most recently served as CEO of Seeker Biologics, and before that as President of Translate Bio prior to its acquisition by Sanofi.

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private equity, CDK2, Patient, Foresite Capital, Eli Lilly and Company, New Enterprise Associates, Therapy, OrbiMed, NEA, OncoMed, Pharmaceutical industry

(“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.

Key Points: 
  • (“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.
  • The total capital raised since the company’s founding in August 2022 is $347 million.
  • In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors.
  • “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo.

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Polaris Partners, Cell, General partnership, Venture round, RNA, Messenger, Bristol Myers Squibb, MBA, Bayer, Therapy, OrbiMed, Immune system, Eli Lilly and Company, Series, Investment, Blood, Vaccine

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.
  • The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments.
  • The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.
  • “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.

GlobalData Report Highlights Staggering Economic Costs for Pennsylvania of $19.9 Billion Due to Obesity

Retrieved on: 
Tuesday, March 19, 2024
Public Policy, Government, Healthcare Reform, General Health, Health, Death, Overweight, Culture, Comment, Disease, Federation, Education, Conditional sentence, Head, Weight loss, GlobalData, News, Insurance, Woman, Parity, Medicaid, Workforce, DSM-IV codes, Eli Lilly and Company, Welfare, Medicare, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on Pennsylvania's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Pennsylvania, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on Pennsylvania's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Pennsylvania, as well as the impact on state tax revenue collections and costs.
  • In Pennsylvania, approximately one-third of adults are classified as having obesity (33.4%), and another third have overweight (34.3%) in 2022.
  • Employers in Pennsylvania paid an extra $2.3 billion in higher medical expenditures for health complications attributed to obesity and overweight.
  • The Obesity Action Coalition’s Stop Obesity Weight Bias Campaign includes media guidelines and bias-free image gallery .

GlobalData Report Highlights Staggering Economic Costs for Alabama of $7.2 Billion Due to Obesity

Retrieved on: 
Thursday, March 14, 2024
Public Policy, Government, Healthcare Reform, Health, Fitness & Nutrition, Labor, General Health, Death, Overweight, Culture, Comment, Disease, Federation, Education, Conditional sentence, Head, Weight loss, GlobalData, Insurance, Woman, Parity, Medicaid, Workforce, DSM-IV codes, Eli Lilly and Company, Welfare, Medicare

GlobalData’s report, ‘ Obesity’s Impact on Alabama's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Alabama, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on Alabama's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of Alabama, as well as the impact on state tax revenue collections and costs.
  • Obesity is a serious, progressive disease and is associated with a range of other diseases, including type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
  • In Alabama, approximately one-third of adults are classified as having obesity (38.3%), and another third have overweight (33.7%) in 2022.
  • Employers in Alabama paid an extra $822 million in higher medical expenditures for health complications attributed to obesity and overweight.